Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 6/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LHCGR | P22888 | 2/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | CCR3 | P51677 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13104206 | 0.98 | F10 (0.44) | F10EPHX2LHCGRCFTRTSHR | |
| SCHEMBL12101397 | 0.98 | F10 (0.44) | F10EPHX2LHCGRCFTRTSHR | |
| SCHEMBL15436018 | 0.87 | F10 (0.48) | F10TSHRKMT2AKLKB1 | |
| SCHEMBL12371451 | 0.87 | F10 (0.48) | F10TSHRKMT2AKLKB1 | |
| SCHEMBL8471226 | 0.87 | F10 (0.54) | F10TSHRKMT2ACYP2C9KLKB1 | |
| SCHEMBL13104152 | 0.84 | F10 (0.52) | F10CFTRTSHRKMT2ACYP2C9 | |
| SCHEMBL13104224 | 0.84 | F10 (0.46) | F10KMT2AKLKB1 | |
| SCHEMBL12101291 | 0.84 | F10 (0.52) | F10CFTRTSHRKMT2ACYP2C9 | |
| SCHEMBL8224896 | 0.84 | F10 (0.46) | F10KMT2AKLKB1 | |
| SCHEMBL12371471 | 0.84 | F10 (0.46) | F10TSHRKMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-8003639-B2 | Substituted prolinamides, the preparation thereof and the use thereof as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-23 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048231-A1 | SUBSTITUTED PROLINAMIDES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PREP, P4HA1, PPID | F10 1628/4885EPHX2 4019/4885LHCGR 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.